MAIA Expands U.S. Clinical Sites for NSCLC Therapy Trial — MAIA Biotechnology, Inc.

Event summary

MAIA Biotechnology activated its second U.S. clinical site for the Phase 2 THIO-101 expansion trial at Central Alabama Research in Homewood, Alabama.
The trial evaluates ateganosine as a third-line treatment for non-small cell lung cancer (NSCLC) in patients who have previously failed checkpoint inhibitors and chemotherapy.
The expansion trial is ongoing in Europe and Asia with 44 active sites in 6 countries, alongside the 2 U.S. sites.
MAIA is also screening and enrolling patients in a pivotal Phase 3 clinical trial designed to assess overall survival for ateganosine sequenced with a checkpoint inhibitor.
The global non-small cell lung cancer market is projected to reach $70 billion by 2030.

The big picture

MAIA Biotechnology's expansion of its Phase 2 THIO-101 trial to a second U.S. clinical site underscores its strategic push to accelerate the development of ateganosine, a novel therapy for non-small cell lung cancer. The move comes as the company aims to capitalize on the projected $70 billion global NSCLC market by 2030, leveraging regulatory pathways like the FDA Fast Track designation to expedite approval. The broader industry context includes a growing emphasis on targeted immunotherapies and the need for effective treatments for patients who have exhausted standard-of-care options.

What we're watching

Regulatory Momentum: Whether the additional data from the THIO-101 expansion trial will further support an accelerated approval filing with the FDA.
Patient Enrollment: The pace at which MAIA can enroll patients across the expanded clinical sites, particularly in underserved and rural populations.
Market Strategy: How MAIA will leverage the Phase 2 and Phase 3 trial data to position ateganosine in the competitive NSCLC market.